NYSE:BSX

Boston Scientific - BSX Stock Forecast, Price & News

$38.14

-0.22 (-0.57%)

(As of 09/27/2022 12:00 AM ET)

Add

Compare

Today's Range: $37.75
▼
$38.80
50-Day Range: $37.28
▼
$43.46
52-Week Range: $34.98
▼
$47.49

Volume: 6.48 million shs
Average Volume: 6.14 million shs
Market Capitalization: $54.52 billion

P/E Ratio: 65.76
Dividend Yield: N/A
Price Target: $46.83

Boston Scientific MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 22.8% Upside
$46.83 Price Target
Short Interest: Healthy
1.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: 0.51
Based on 8 Articles This Week
Insider Trading: Selling Shares
$2.43 M Sold Last Quarter
Proj. Earnings Growth: 11.36%
From $1.76 to $1.96 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

36th out of 1,071 stocks

Surgical & Medical Instruments Industry

3rd out of 106 stocks

3.5

Analyst's Opinion

Consensus Rating
Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $46.83, Boston Scientific has a forecasted upside of 22.8% from its current price of $38.14.
Amount of Analyst Coverage
Boston Scientific has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.13% of the outstanding shares of Boston Scientific have been sold short.
Short Interest Ratio / Days to Cover
Boston Scientific has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Boston Scientific has recently increased by 5.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Boston Scientific does not currently pay a dividend.
Dividend Growth
Boston Scientific does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Boston Scientific has received a 69.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Cardiac resynchronization therapy (CRT) devices", and "Catheters" products. See details.
Environmental Sustainability
The Environmental Impact score for Boston Scientific is -0.88.

2.0

News and Social Media Coverage

News Sentiment
Boston Scientific has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Boston Scientific this week, compared to 6 articles on an average week.
Search Interest
Only 8 people have searched for BSX on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,433,248.00 in company stock.
Percentage Held by Insiders
Only 0.66% of the stock of Boston Scientific is held by insiders.
Percentage Held by Institutions
90.33% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Boston Scientific are expected to grow by 11.36% in the coming year, from $1.76 to $1.96 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Boston Scientific is 65.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.20.
Price to Earnings Ratio vs. Sector
The P/E ratio of Boston Scientific is 65.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.61.
Price to Earnings Growth Ratio
Boston Scientific has a PEG Ratio of 2.08. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Boston Scientific has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

September 27, 2022 | finance.yahoo.com

Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay

September 27, 2022 | finance.yahoo.com

Is It Time To Consider Buying Boston Scientific Corporation (NYSE:BSX)?

September 25, 2022 | msn.com

Family demands Boston Public Schools hire more bus drivers after student in wheelchair is nearly stranded

September 24, 2022 | msn.com

Boston City Council districts 2 and 3 are areas that need to change most under redistricting, data shows

September 23, 2022 | finance.yahoo.com

Healthcare Learned a Lot From Covid. 12 Ways to Invest Now.

September 23, 2022 | msn.com

Cramer's lightning round: I like Boston Scientific over Medtronic

September 23, 2022 | fool.com

Boston Scientific (NYSE: BSX)

September 21, 2022 | americanbankingnews.com

Boston Scientific Co. (NYSE:BSX) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 17, 2022 | finance.yahoo.com

Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL™ Cerebral Protection System

September 9, 2022 | msn.com

4BSX : Where Boston Scientific Stands With Analysts

September 6, 2022 | markets.businessinsider.com

Boston Scientific Gets FDA Approval For Expanded Labeling Of WATCHMAN FLX LAAC Device

September 6, 2022 | finance.yahoo.com

Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

September 2, 2022 | nasdaq.com

Investing in Boston Scientific (NYSE:BSX) five years ago would have delivered you a 44% gain

September 1, 2022 | nasdaq.com

Interesting BSX Put And Call Options For October 14th

August 29, 2022 | finance.yahoo.com

Billionaire Izzy Englander’s Latest Portfolio: Top 10 Stock Picks

August 26, 2022 | nasdaq.com

Interesting BSX Put And Call Options For October 7th

August 25, 2022 | nasdaq.com

Bullish Two Hundred Day Moving Average Cross - BSX

August 22, 2022 | finance.yahoo.com

Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

August 17, 2022 | finance.yahoo.com

Boston Scientific Named a Best Place To Work by Disability:IN

August 17, 2022 | finance.yahoo.com

Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement

August 15, 2022 | benzinga.com

Boston Scientific Adds 'Novel' Technology Via This Acquisition For Interventional Oncology

August 15, 2022 | finance.yahoo.com

Boston Scientific Announces Acquisition of Obsidio, Inc.

August 12, 2022 | nasdaq.com

This Insider Has Just Sold Shares In Boston Scientific Corporation (NYSE:BSX)

August 9, 2022 | seekingalpha.com

Boston Scientific: Strong Earnings Report, But Shares Are Not Cheap Yet

August 8, 2022 | finance.yahoo.com

Boston Scientific Recognized by Seramount's Best Companies for Multicultural Women

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Company Calendar

Last Earnings: 7/27/2022
Today: 9/28/2022
Next Earnings (Estimated): 10/26/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NYSE:BSX
CUSIP: 10113710
CIK: 885725
Web: www.bostonscientific.com
Phone: (508) 683-4000
Fax: 508-683-5675
Employees: 41,000
Year Founded: 1979

Price Target and Rating

Average Stock Price Forecast: $46.83
High Stock Price Forecast: $51.00
Low Stock Price Forecast: $43.00
Forecasted Upside/Downside: +22.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.58
Trailing P/E Ratio: 65.76
Forward P/E Ratio: 21.67
P/E Growth: 2.08
Net Income: $1.04 billion
Net Margins: 7.16%
Pretax Margin: 8.95%
Return on Equity: 14.58%
Return on Assets: 7.60%

Debt

Debt-to-Equity Ratio: 0.51
Current Ratio: 1.31
Quick Ratio: 0.86

Sales & Book Value

Annual Sales: $11.89 billion
Price / Sales: 4.59
Cash Flow: $2.69 per share
Price / Cash Flow: 14.18
Book Value: $11.66 per share
Price / Book: 3.27

Miscellaneous

Outstanding Shares: 1,429,570,000
Free Float: 1,420,136,000
Market Cap: $54.52 billion
Optionable: Optionable
Beta: 0.85

Social Links

Key Executives

Mr. Michael F. Mahoney (Age 57)
Chairman, Pres & CEO
Comp: $3.83M

Mr. Daniel J. Brennan (Age 56)
Exec. VP & CFO
Comp: $1.4M

Mr. Joseph M. Fitzgerald (Age 58)
Exec. VP & Group Pres of Cardiology
Comp: $1.57M

Mr. Jeffrey B. Mirviss (Age 56)
Exec. VP & Pres of Peripheral Interventions
Comp: $1.21M

Mr. John Bradley Sorenson (Age 54)
Exec. VP of Global Operations

Mr. Jonathan R Monson
VP, Global Controller & Chief Accounting Officer

Ms. Jodi Euerle Eddy (Age 49)
Sr. VP and Chief Information & Digital Officer

Ms. Susan Vissers Lisa (Age 53)
VP of Investor Relations

Mr. Vance R. Brown
Sr. VP, Gen. Counsel & Corp. Sec.

Ms. Catherine Jennings
VP of Global Marketing & New Bus. Devel. of Peripheral Interventions

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BSX Stock - Frequently Asked Questions

Should I buy or sell Boston Scientific stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BSX shares.
View BSX analyst ratings or view top-rated stocks.
What is Boston Scientific's stock price forecast for 2022?: 13 Wall Street analysts have issued 1 year price objectives for Boston Scientific's stock. Their BSX share price forecasts range from $43.00 to $51.00. On average, they anticipate the company's share price to reach $46.83 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for BSX or view top-rated stocks among Wall Street analysts.
How have BSX shares performed in 2022?: Boston Scientific's stock was trading at $42.48 at the beginning of 2022. Since then, BSX stock has decreased by 10.2% and is now trading at $38.14.
View the best growth stocks for 2022 here.
Are investors shorting Boston Scientific?: Boston Scientific saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 15,210,000 shares, a decline of 9.8% from the August 15th total of 16,860,000 shares. Based on an average daily volume of 7,390,000 shares, the days-to-cover ratio is currently 2.1 days.
View Boston Scientific's Short Interest.
When is Boston Scientific's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our BSX earnings forecast.
How were Boston Scientific's earnings last quarter?: Boston Scientific Co. (NYSE:BSX) released its quarterly earnings data on Wednesday, July, 27th. The medical equipment provider reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.42 by $0.02. The medical equipment provider had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. Boston Scientific had a trailing twelve-month return on equity of 14.58% and a net margin of 7.16%. The company's revenue was up 5.4% on a year-over-year basis. During the same period last year, the business earned $0.40 EPS.
Read the conference call transcript.
What guidance has Boston Scientific issued on next quarter's earnings?: Boston Scientific issued an update on its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $0.43-$0.45 for the period, compared to the consensus earnings per share estimate of $0.45. The company issued revenue guidance of $3.11 billion-$3.17 billion, compared to the consensus revenue estimate of $3.20 billion.
What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?: 947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Boston Scientific own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and Salesforce (CRM).
What is Boston Scientific's stock symbol?: Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
Who are Boston Scientific's major shareholders?: Boston Scientific's stock is owned by a number of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (2.65%), DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (1.46%), Artisan Partners Limited Partnership (1.35%), Parnassus Investments LLC (1.10%), Northern Trust Corp (0.97%) and Lazard Asset Management LLC (0.89%). Insiders that own company stock include Arthur C Butcher, Arthur C Butcher, Daniel J Brennan, David A Pierce, David A Pierce, David S Wichmann, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Ian T Meredith, Jeffrey B Mirviss, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Jonathan Monson, Joseph Michael Fitzgerald, Maulik Nanavaty, Meghan Scanlon, Michael F Mahoney, Michael F Mahoney, Nelda J Connors, Scott Olson, Wendy Carruthers, William F Bruss and Williamson Scott.
View institutional ownership trends.
How do I buy shares of Boston Scientific?: Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Boston Scientific's stock price today?: One share of BSX stock can currently be purchased for approximately $38.14.
How much money does Boston Scientific make?: Boston Scientific (NYSE:BSX) has a market capitalization of $54.52 billion and generates $11.89 billion in revenue each year. The medical equipment provider earns $1.04 billion in net income (profit) each year or $0.58 on an earnings per share basis.
How many employees does Boston Scientific have?: The company employs 41,000 workers across the globe.
Does Boston Scientific have any subsidiaries?: The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.
Read More
How can I contact Boston Scientific?: Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The official website for the company is www.bostonscientific.com. The medical equipment provider can be reached via phone at (508) 683-4000, via email at bsxinvestorrelations@bsci.com, or via fax at 508-683-5675.

This page (NYSE:BSX) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Boston Scientific - BSX Stock Forecast, Price & News

Boston Scientific MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows